Senseonics Holdings has partnered with diabetes management companies Roche Diabetes Care and TypeZero Technologies to develop a long-term automated insulin delivery system.
The new system will be used in the international diabetes closed loop (IDCL) clinical trial, which is being funded by the US National Institutes of Health (NIH) to evaluate automated insulin delivery devices.
Go deeper with GlobalData
IDCL is designed to integrate Senseonics’ long-term, implantable continuous glucose monitoring (CGM) system Eversense with Roche’s Accu-Chek Insight Insulin Pump, and TypeZero’s inControl AP algorithms.
Eversense features a small, fluorescence sensing technology-based CGM sensor that lasts for approximately 90 days.
Upon subcutaneous insertion, the sensor continually measures glucose levels and wirelessly transmits them to a mobile application via a smart transmitter.
inControl software has been developed to use the combination of data obtained from the CGM system and the pump for automatic adjustment and regulation of insulin delivery.
Senseonics president and CEO Tim Goodnow said: "The promise of automated insulin delivery systems is the ability to automatically and sustainably maintain tight glucose control while avoiding hypoglycaemia.
"With this partnership, we are one step closer to bringing this promise to market and to significantly improve the everyday challenges of people with diabetes."
Aimed at reducing the burden of disease for diabetic patients, the IDCL trial will be conducted at the University of Amsterdam in the Netherlands, Italy's University of Padova, and France's University Hospital of Montpellier.
